Treatment of pemphigus with gold

Amit G. Pandya, Christopher Dyke

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background: Although gold has been reported to be useful in treating pemphigus vulgaris, its use has waned in recent years because of concerns regarding efficacy and toxicity. Objective: To review 26 patients with pemphigus who were treated with intramuscular gold over a 10-year period. Results: Gold was effective in 62% of patients as a primary treatment for pemphigus or as a steroid-sparing agent. An average of 3 months of therapy was required before the daily prednisone dosage could be halved. Four patients were free of disease and stopped receiving all therapy at the conclusion of the study. Toxic effects due to gold therapy developed in 42% of patients and all adverse effects resolved with its cessation. Conclusions: While toxic effects limit the use of gold in many patients with pemphigus, it may be effective in treating a large percentage of patients who otherwise are unable to reduce their steroid requirement. Because of its delayed onset of action, patients treated with gold usually require systemic steroids when therapy is initiated. Controlled, prospective trials are needed to further evaluate the efficacy of gold and its potential steroid-sparing effects.

Original languageEnglish (US)
Pages (from-to)1104-1107
Number of pages4
JournalArchives of Dermatology
Volume134
Issue number9
DOIs
StatePublished - Sep 1998

Fingerprint

Pemphigus
Gold
Steroids
Poisons
Therapeutics
Prednisone

ASJC Scopus subject areas

  • Dermatology

Cite this

Treatment of pemphigus with gold. / Pandya, Amit G.; Dyke, Christopher.

In: Archives of Dermatology, Vol. 134, No. 9, 09.1998, p. 1104-1107.

Research output: Contribution to journalArticle

Pandya, Amit G. ; Dyke, Christopher. / Treatment of pemphigus with gold. In: Archives of Dermatology. 1998 ; Vol. 134, No. 9. pp. 1104-1107.
@article{aafafef1666f40e78414b47abd8ffc24,
title = "Treatment of pemphigus with gold",
abstract = "Background: Although gold has been reported to be useful in treating pemphigus vulgaris, its use has waned in recent years because of concerns regarding efficacy and toxicity. Objective: To review 26 patients with pemphigus who were treated with intramuscular gold over a 10-year period. Results: Gold was effective in 62{\%} of patients as a primary treatment for pemphigus or as a steroid-sparing agent. An average of 3 months of therapy was required before the daily prednisone dosage could be halved. Four patients were free of disease and stopped receiving all therapy at the conclusion of the study. Toxic effects due to gold therapy developed in 42{\%} of patients and all adverse effects resolved with its cessation. Conclusions: While toxic effects limit the use of gold in many patients with pemphigus, it may be effective in treating a large percentage of patients who otherwise are unable to reduce their steroid requirement. Because of its delayed onset of action, patients treated with gold usually require systemic steroids when therapy is initiated. Controlled, prospective trials are needed to further evaluate the efficacy of gold and its potential steroid-sparing effects.",
author = "Pandya, {Amit G.} and Christopher Dyke",
year = "1998",
month = "9",
doi = "10.1001/archderm.134.9.1104",
language = "English (US)",
volume = "134",
pages = "1104--1107",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Treatment of pemphigus with gold

AU - Pandya, Amit G.

AU - Dyke, Christopher

PY - 1998/9

Y1 - 1998/9

N2 - Background: Although gold has been reported to be useful in treating pemphigus vulgaris, its use has waned in recent years because of concerns regarding efficacy and toxicity. Objective: To review 26 patients with pemphigus who were treated with intramuscular gold over a 10-year period. Results: Gold was effective in 62% of patients as a primary treatment for pemphigus or as a steroid-sparing agent. An average of 3 months of therapy was required before the daily prednisone dosage could be halved. Four patients were free of disease and stopped receiving all therapy at the conclusion of the study. Toxic effects due to gold therapy developed in 42% of patients and all adverse effects resolved with its cessation. Conclusions: While toxic effects limit the use of gold in many patients with pemphigus, it may be effective in treating a large percentage of patients who otherwise are unable to reduce their steroid requirement. Because of its delayed onset of action, patients treated with gold usually require systemic steroids when therapy is initiated. Controlled, prospective trials are needed to further evaluate the efficacy of gold and its potential steroid-sparing effects.

AB - Background: Although gold has been reported to be useful in treating pemphigus vulgaris, its use has waned in recent years because of concerns regarding efficacy and toxicity. Objective: To review 26 patients with pemphigus who were treated with intramuscular gold over a 10-year period. Results: Gold was effective in 62% of patients as a primary treatment for pemphigus or as a steroid-sparing agent. An average of 3 months of therapy was required before the daily prednisone dosage could be halved. Four patients were free of disease and stopped receiving all therapy at the conclusion of the study. Toxic effects due to gold therapy developed in 42% of patients and all adverse effects resolved with its cessation. Conclusions: While toxic effects limit the use of gold in many patients with pemphigus, it may be effective in treating a large percentage of patients who otherwise are unable to reduce their steroid requirement. Because of its delayed onset of action, patients treated with gold usually require systemic steroids when therapy is initiated. Controlled, prospective trials are needed to further evaluate the efficacy of gold and its potential steroid-sparing effects.

UR - http://www.scopus.com/inward/record.url?scp=0031709341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031709341&partnerID=8YFLogxK

U2 - 10.1001/archderm.134.9.1104

DO - 10.1001/archderm.134.9.1104

M3 - Article

C2 - 9762022

AN - SCOPUS:0031709341

VL - 134

SP - 1104

EP - 1107

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 9

ER -